December 15, 2025
Headlines

Biotech

Dr.-Jinquan-Sun-co-Founder-of-Convergen

Convergen Raises $10M Seed to Advance TrimTAC Platform for Targeted Protein Degradation in Neurodegenerative Diseases – News

Editor04 mins

Biotech startup Convergen has closed $10 million in Seed funding to accelerate development of its TrimTAC platform, a next-generation targeted protein degradation (TPD) technology designed to selectively clear pathogenic protein aggregates. The round was led by Qiming Venture Partners, a leading global venture capital firm specializing in healthcare and life sciences. Convergen’s proprietary TrimTAC platform…

Read More
Dr. Patrick Trojer, President and CEO of TRIANA Biomedicines

TRIANA Biomedicines Secures Oversubscribed $120 Million Series B to Advance Molecular Glue Degrader Pipeline

Editor06 mins

TRIANA Biomedicines said on Thursday it had closed an oversubscribed $120 million Series B financing, strengthening its push to bring a new class of molecular glue degraders into the clinic, including its lead candidate, TRI-611, for patients with ALK-positive non-small cell lung cancer (NSCLC). The round was co-led by new investors (Ascenta Capital) and (Bessemer…

Read More
Junevity

Junevity Closes $20 Million Seed Round to Pioneer Cell Reprogramming with siRNA for Type 2 Diabetes and Obesity

Editor07 mins

Junevity, a pioneering biotechnology company with the ambitious mission of extending human healthspan through advanced cell reprogramming, today announced it has successfully expanded its Seed financing to a total of $20 million with an additional $10 million investment. The new capital was jointly led by Goldcrest Capital and Godfrey Capital, providing the runway necessary to…

Read More
Pavle Jeremić, CEO and Founder of Aether Biomachines

Aether Biomachines Secures $15M to Deploy AI-Designed Proteins, Accelerating America’s Industrial Independence

Editor07 mins

Aether Biomachines, an American artificial intelligence company focused on delivering real-world industrial solutions using AI-designed proteins, today announced it has raised an additional $15 million in funding. The round was led by Tribe Capital, with significant participation from both new and existing investors, including Natural Capital, Henkel Corporation, Resilience Reserve, Shrug Capital, 4DX Ventures, Unless…

Read More
Morphocell Technologies

A US$50M Raise Positions Morphocell Technologies at the Center of Regenerative Medicine’s Next Phase

Editor08 mins

In an industry where clinical timelines stretch a decade and financing cycles can make or break scientific ambition, Morphocell Technologies has pulled off a milestone that places it among Canada’s most serious regenerative-medicine contenders. The Montreal-based biotechnology company has completed its full US$50 million Series A raise, adding a fresh US$10 million extension round led…

Read More

Uluu Raises $16 Million to Turn Seaweed into the Next Global Plastic Alternative

Editor07 mins

In a pivotal moment for the materials industry, Australian start-up Uluu has secured AU$16 million in its Series A funding round to build a demonstration facility capable of scaling its seaweed-derived plastic alternative. Headquartered in Perth, Western Australia, the company plans to move from its current 100 kg/year pilot plant to a 10-tonne/year demonstration plant…

Read More
CEO Benny Sørensen, MD, PhD,

Hemab Therapeutics Raises $157 Million to Transform the Future of Rare Bleeding Disorder Care

Editor04 mins

For a biotech world often focused on oncology and gene editing, Hemab Therapeutics has carved out a very different frontier: rare, inherited bleeding disorders that have long gone overlooked. The company has raised $157 million in a Series C round, a multifold oversubscribed financing led by Sofinnova Partners, with participation from a global sovereign wealth…

Read More

$17.25 Million Boost for VitriVax Signals a Shift in How Vaccines Could Reach the Unreached

Editor04 mins

When biotech firm VitriVax raised $17.25 million in a Series B funding round, co-led by Adjuvant Capital and RA Capital Management, LP, it revealed more than just money changing hands—it spotlighted a broader fracture point in global immunisation strategy. Based in Boulder, Colorado, VitriVax is tackling two fundamental hurdles in vaccine delivery: the cold-chain barrier and the logistical burden…

Read More

Redefining Immune Therapy: Electra Therapeutics Raises $183 Million to Battle Deadly Hyperinflammation and Cancer

Editor07 mins

In the complex world of immune-mediated diseases, where treatment options often fall short, Electra Therapeutics is carving a distinct path. The late-stage biotech, based in the U.S., has secured a robust $183 million in Series C funding to advance its groundbreaking precision therapies targeting severe immunological conditions and hematologic cancers. The financing round, co-led by…

Read More

Peptilogics’ $78M Raise Signals a New Era in Surgical Therapeutics—One That Finally Confronts Biofilm

Editor05 mins

In a crowded biotech landscape where antibiotic breakthroughs rarely break through, Peptilogics has secured a commanding $78 million in an oversubscribed Series B2 round to fuel its pivotal trial of zaloganan (PLG0206), a therapeutic candidate aimed at prosthetic joint infections (PJI). The financing was led by Presight Capital, Thiel Bio, and Founders Fund, with fresh capital from…

Read More